Wolverine Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Wolverine Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,012	Closed	-$70.6K	–	1829
2025 Q4	$70.6K	Sell	2,012 -417	-17%	-$15.2K	﹤0.01%	1234
2025 Q3	$69.1K	Buy	+2,429	New	+$58.2K	﹤0.01%	1156
2024 Q4	–	Sell	-4,944	Closed	-$82.1K	–	1743
2024 Q3	$82.1K	Sell	4,944 -10,580	-68%	-$183K	﹤0.01%	1130
2024 Q2	$298K	Buy	15,524 +8,394	+118%	+$168K	﹤0.01%	932
2024 Q1	$169K	Sell	7,130 -1,564	-18%	-$31.7K	﹤0.01%	986
2023 Q4	$97.1K	Buy	8,694 +5,769	+197%	+$52.8K	﹤0.01%	1130
2023 Q3	$27.1K	Buy	+2,925	New	+$31.7K	﹤0.01%	1318
2023 Q2	–	Sell	-4,819	Closed	-$63.9K	–	1889
2023 Q1	$63.9K	Buy	+4,819	New	+$60.8K	﹤0.01%	1174

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Wolverine Asset Management's NAMS Position: Q1 2026 in Review

Wolverine Asset Management sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 2,012 shares — an estimated $70.6K sold.

Wolverine Asset Management first reported a position in NAMS in Q1 2023 and held it in 8 quarters. The position peaked at $298K in Q2 2024. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Wolverine Asset Management reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
Wolverine Asset Management sold 2,012 NewAmsterdam Pharma shares in Q1 2026, an estimated $70.6K.
Wolverine Asset Management first reported a position in NewAmsterdam Pharma in Q1 2023 and held it in 8 quarters.
Wolverine Asset Management's NewAmsterdam Pharma position peaked at $298K in Q2 2024.
171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.